Mitapivat cut transfusions in thalassaemia, but not for most patients

Mitapivat, an oral drug that boosts a key enzyme inside red blood cells, cut the number of blood transfusions needed by adults with transfusion-dependent thalassaemia in a phase 3 trial [s1]. But the benefit reached a minority: about 30% of patients on the drug met the trial's transfusion-reduction target over 48 weeks, against 13% on placebo — a real effect that its maker, Agios, presents as the first oral disease-modifying therapy for the inherited blood disorder [s1].

Thalassaemia is a group of inherited disorders in which the body makes faulty or too little haemoglobin, the protein that carries oxygen [s1]. In its transfusion-dependent forms, patients rely on regular red-cell transfusions to survive, a burden that brings iron overload and its own organ damage over a lifetime [s1]. Until now there has been no oral disease-modifying treatment for α-thalassaemia and none of that kind for β-thalassaemia — the gap the trial set out to address [s1].

What ENERGIZE-T tested

ENERGIZE-T was a double-blind, randomised, placebo-controlled phase 3 trial run across 19 countries [s1]. It enrolled 258 adults with transfusion-dependent α- or β-thalassaemia, randomly assigning them 2:1 to mitapivat 100 mg or placebo, taken orally twice a day for 48 weeks [s1].

The primary endpoint was a transfusion-reduction response, defined precisely: a drop of at least 50% in the number of red-cell units transfused, and of at least two units, across any consecutive 12-week window compared with each patient's own baseline [s1]. That threshold matters for reading the result — it measures a substantial cut in transfusion burden, not freedom from transfusion.

A response occurred in 52 of 171 patients on mitapivat (30%) and 11 of 87 on placebo (13%), an adjusted difference of 18 percentage points (95% CI 8 to 27; p=0.0003) [s1]. Serious adverse events were reported in 11% of the mitapivat group and 15% of the placebo group, and 6% of mitapivat patients discontinued for adverse events versus 1% on placebo [s1]. Adverse events overall were common in both arms — 90% on mitapivat and 84% on placebo — with headache, upper respiratory tract infection, initial insomnia, diarrhoea and fatigue the most frequent on the drug [s1]. No deaths were reported [s1].

The honest read

The effect is statistically clear and clinically meaningful for those it helps, but it is partial. Roughly seven in ten patients on mitapivat did not meet the response threshold, and the endpoint measured a reduction in transfusions rather than independence from them [s1]. For a lifelong condition, the questions that most affect patients — whether reduced transfusions translate into less iron overload and fewer organ complications over years, and how durable the effect is — are beyond what a 48-week trial can answer.

Mitapivat is not a new molecule. It works as an allosteric activator of pyruvate kinase, an enzyme that helps red blood cells generate energy, and the U.S. Food and Drug Administration first approved it in February 2022, under the brand Pyrukynd, for a different rare anaemia — pyruvate kinase deficiency [s2]. ENERGIZE-T extends an already-approved drug into a new, larger group of blood disorders, which is part of why a moderate response rate still counts as progress: it is an oral option in a field where the alternatives are transfusions, iron chelation, and, for a minority, stem-cell transplant or gene therapy.

Where it sits among the options

The most definitive treatments for severe thalassaemia are one-time and expensive: allogeneic stem-cell transplant, and more recently gene therapies and gene-editing approaches of the kind Health Newspapers has covered in sickle cell disease with CRISPR editing and in the wider access gap for curative therapies. A daily pill that meaningfully lowers transfusion needs for a subset of patients is a different kind of offering — incremental and manageable rather than curative — and its value will depend heavily on price and on who responds. The scale of the underlying need is why screening programmes exist, such as the premarital genomic screening reviewed in Dubai.

What to watch

The trial is registered as active but not recruiting, with an open-label extension that should report on longer-term safety and durability [s1]. The decisions ahead are regulatory — whether agencies approve mitapivat for thalassaemia on the strength of a transfusion-reduction endpoint — and practical: which patients are most likely to respond, and whether the reduction in transfusions seen over a year holds up and feeds through to the organ outcomes that determine how people with thalassaemia actually fare [s1].

This article describes research and regulatory status and is not medical advice. Treatment for thalassaemia is individualised and decided with a haematology team.